Disruptive Strategies for Removing Drug Discovery Bottlenecks

Content Provider	Semantic Scholar
Author	Ekins, Sean Waller, Chris L. Bradley, Mary P. Williams, Antony J.
Copyright Year	2012
Abstract	Drug Discovery is shifting focus from the industry to outside partners and in the process creating new bottlenecks, suggesting the need for a more disruptive overhaul. Technologies like high throughput screening (HTS) have moved to a larger number of academic and institutional laboratories in the US, with little apparent coordination or consideration of the outputs and creating a translational gap. While there have been collaborative public private partnerships in Europe to share pharmaceutical data, the USA has lagged behind. Sharing precompetitive computational models may be the next frontier to provide more confidence in the quality of the leads produced and attract investment. We suggest there needs to be an awareness of what research is going on in the screening centers, more collaboration and coordination. These efforts will shift the focus to finding the best researchers to fund and require a rethink of how to reward their collaborative efforts.
Starting Page	1
Ending Page	1
Page Count	1
File Format	PDF HTM / HTML
DOI	10.1038/npre.2012.6961.1
Volume Number	7
Alternate Webpage(s)	http://precedings.nature.com/documents/6961/version/1/files/npre20126961-1.pdf
Alternate Webpage(s)	https://doi.org/10.1038/npre.2012.6961.1
Language	English
Access Restriction	Open
Content Type	Text
Resource Type	Article